Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4534113
Max Phase: Preclinical
Molecular Formula: C165H252N42O52
Molecular Weight: 3656.07
Molecule Type: Unknown
Associated Items:
ID: ALA4534113
Max Phase: Preclinical
Molecular Formula: C165H252N42O52
Molecular Weight: 3656.07
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(N)=O)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)CC
Standard InChI: InChI=1S/C165H252N42O52/c1-23-80(12)127(158(253)181-86(18)138(233)190-112(62-94-68-174-99-42-33-32-41-97(94)99)150(245)193-108(58-79(10)11)152(247)203-128(81(13)24-2)159(254)187-102(49-51-119(168)216)144(239)204-130(87(19)211)161(256)186-100(43-34-35-53-166)143(238)201-129(82(14)25-3)160(255)207-133(90(22)214)162(257)188-104(134(169)229)64-123(221)222)202-153(248)110(59-91-37-28-26-29-38-91)194-151(246)115(67-126(227)228)196-141(236)101(44-36-54-173-165(170)171)184-136(231)84(16)178-135(230)83(15)179-145(240)105(55-76(4)5)189-137(232)85(17)180-146(241)114(66-125(225)226)197-147(242)106(56-77(6)7)192-149(244)109(61-93-45-47-96(215)48-46-93)198-163(258)131(88(20)212)206-157(252)118(74-210)199-148(243)107(57-78(8)9)191-142(237)103(50-52-122(219)220)185-156(251)117(73-209)200-164(259)132(89(21)213)205-154(249)111(60-92-39-30-27-31-40-92)195-155(250)116(72-208)183-121(218)71-176-140(235)113(65-124(223)224)182-120(217)70-175-139(234)98(167)63-95-69-172-75-177-95/h26-33,37-42,45-48,68-69,75-90,98,100-118,127-133,174,208-215H,23-25,34-36,43-44,49-67,70-74,166-167H2,1-22H3,(H2,168,216)(H2,169,229)(H,172,177)(H,175,234)(H,176,235)(H,178,230)(H,179,240)(H,180,241)(H,181,253)(H,182,217)(H,183,218)(H,184,231)(H,185,251)(H,186,256)(H,187,254)(H,188,257)(H,189,232)(H,190,233)(H,191,237)(H,192,244)(H,193,245)(H,194,246)(H,195,250)(H,196,236)(H,197,242)(H,198,258)(H,199,243)(H,200,259)(H,201,238)(H,202,248)(H,203,247)(H,204,239)(H,205,249)(H,206,252)(H,207,255)(H,219,220)(H,221,222)(H,223,224)(H,225,226)(H,227,228)(H4,170,171,173)/t80-,81-,82-,83-,84-,85-,86-,87+,88+,89+,90+,98-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,127-,128-,129-,130-,131-,132-,133-/m0/s1
Standard InChI Key: KJOWEZOEOWJCON-OSQUNABVSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 3656.07 | Molecular Weight (Monoisotopic): 3653.8366 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Suzuki R, Brown GA, Christopher JA, Scully CCG, Congreve M.. (2020) Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors., 63 (3): [PMID:31577440] [10.1021/acs.jmedchem.9b00835] |
Source(1):